認知症患者への処方箋:ロードマップ
Ariel R Green1, Cynthia M Boyd2, Rosalphie Quiles2
1Division of Geriatric Medicine and Gerontology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA. ariel@jhmi.edu.
Drugs & aging
|August 26, 2025
まとめ
認知症 (PWD) の患者に不必要な薬を処方することは 害を減らすために極めて重要です このガイドは,PWDとそのパートナーのケアを改善し,安全な薬物離脱のためのロードマップを提供します.
科学分野:
- 高齢者医療
- 薬理学について
- 神経学
背景:
- 認知症 (PWD) の患者はしばしばポリファーマと潜在的に不適切な薬 (PIM) の使用に直面し,リスクを高めます.
- 薬剤のリスクは,PWDの治療目標と相違したり,利益を上回ったりします.
- 適切な処方箋は 質の高い認知症ケアに不可欠で 患者と介護パートナーにとって 害を防止し 福祉を向上させます
研究 の 目的:
- PWDにおけるポリファーマシーのリスクを見直す.
- この集団における安全性と有効性の証拠を検証する.
- 認知症に関連するユニークな課題に取り組むために,PWDのうつ病診断のための実践的なロードマップを提供すること.
主な方法:
- 高齢者のための既存の処方枠組のレビュー
- 認知症に特異的な問題である疾患の変異性や行動症状に対処するための枠組みの適応
- PWDの減量のための段階的なロードマップの開発.
- 患者と介護パートナーのためのコミュニケーション戦略を含みます.
主要な成果:
- 多剤薬は認知症の患者に重大なリスクをもたらします
- 処方箋は PWD 患者にとって 安全で効果的です
- 目標の誘導,計画の縮小,フォローアップを含む,構造化されたアプローチが提案されています.
- コミュニケーション戦略は,共同意思決定を容易にするように調整されています.
結論:
- 高品質な認知症の治療には 処方箋は不可欠です
- 提案されたロードマップは,PWDの薬物離脱に対する構造的なアプローチを提供します.
- 患者とケアパートナーとの 効果的なコミュニケーションは 処方停止の成功の鍵です
- このアプローチは,PWDの健康成果を向上させ,陽性ダメージを減らすことを目的としています.
関連する概念動画
Drug Dosing: Geriatric Patients
104
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
104
Pharmacodynamics in Geriatric Patients: Effects of Age
99
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
99
Alzheimer's Disease: Treatment
586
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
586
Dementia
291
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
291
Drug Therapy
154
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
154
Alzheimer's Disease: Overview
1.1K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.1K


